FRA1 drives melanoma metastasis through an actionable transcriptional network

Transcriptional dysregulation has emerged as a critical driver of melanoma progression, yet the molecular mechanisms governing this process and their potential as therapeutic targets remain inadequately characterized. Here, we identify FRA1 as a potent and actionable driver of melanoma metastasis. FRA1 enhanced both the initial seeding and subsequent outgrowth of metastatic lesions. Comprehensive multi-omics integration revealed transcriptional target genes of FRA1, with AXL, CDK6, and FSCN1 exhibiting increased expression in melanoma metastasis and a significant correlation with poor patient outcomes. Silencing AXL, CDK6, or FSCN1 abrogated FRA1-mediated invasion in vitro and reduced metastatic colonization. Furthermore, pharmacological inhibition of CDK6 and FSCN1, and to a lesser extent AXL, suppressed melanoma metastasis and prolonged overall survival. The expression of FRA1 and its target genes correlates with shortened survival across multiple cancer types, highlighting the broader clinical relevance of this pathway. This study unveils an actionable FRA1-mediated transcriptional network that drives cancer progression and metastasis, offering potential avenues for therapeutic interventions.

Authors

Institutions

Publication Details

Journal
Oncogene
Published
2025-11-24
DOI
https://doi.org/10.1038/s41388-025-03632-5
Citations
1
Primary Topic
Melanoma and MAPK Pathways
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FRA1 drives melanoma metastasis through an actionable transcriptional network

Florian A. Karreth, Shaaron Ochoa-Rios, Nicol Mecozzi, Manon Chadourne et al.
1 citations
Oncogene
Melanoma and MAPK Pathways
0.81
article

FRA1 drives melanoma metastasis through an actionable transcriptional network

Florian A. Karreth, Shaaron Ochoa-Rios, Nicol Mecozzi, Manon Chadourne, Kaizhen Wang, Jiqiang Yao, Neel Jasani, Zulaida Soto-Vargas, Xiaonan Xu, Xiaoqing Yu, Vinesh Jarajapu
article en
1 citations

Abstract

Transcriptional dysregulation has emerged as a critical driver of melanoma progression, yet the molecular mechanisms governing this process and their potential as therapeutic targets remain inadequately characterized. Here, we identify FRA1 as a potent and actionable driver of melanoma metastasis. FRA1 enhanced both the initial seeding and subsequent outgrowth of metastatic lesions. Comprehensive multi-omics integration revealed transcriptional target genes of FRA1, with AXL, CDK6, and FSCN1 exhibiting increased expression in melanoma metastasis and a significant correlation with poor patient outcomes. Silencing AXL, CDK6, or FSCN1 abrogated FRA1-mediated invasion in vitro and reduced metastatic colonization. Furthermore, pharmacological inhibition of CDK6 and FSCN1, and to a lesser extent AXL, suppressed melanoma metastasis and prolonged overall survival. The expression of FRA1 and its target genes correlates with shortened survival across multiple cancer types, highlighting the broader clinical relevance of this pathway. This study unveils an actionable FRA1-mediated transcriptional network that drives cancer progression and metastasis, offering potential avenues for therapeutic interventions.

OncogeneVol. 44(50)
University of South Florida (US), Moffitt Cancer Center (US), Molecular Oncology (United States) (US)
Melanoma Research Alliance, Florida Department of Health, National Institutes of Health, National Cancer Institute
Openalex Percentile: Top 21%
Melanoma and MAPK Pathways
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.